<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="3">
  <stage>Registered</stage>
  <submitdate>7/07/2005</submitdate>
  <approvaldate>8/07/2005</approvaldate>
  <actrnumber>ACTRN12605000002684</actrnumber>
  <trial_identification>
    <studytitle>A randomised controlled trial to evaluate the effect of modified constraint induced movement therapy or conventional occupational therapy following injection of botulinum toxin-A to improve bimanual performance in children with hemiplegic cerebral palsy.</studytitle>
    <scientifictitle>A randomised controlled trial to evaluate the effect of modified constraint induced movement therapy or conventional occupational therapy following injection of botulinum toxin-A to improve bimanual performance in children with hemiplegic cerebral palsy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemiplegic Cerebral Palsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Physical Medicine / Rehabilitation</conditioncode1>
      <conditioncode2>Occupational therapy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Study Group - Upper limb injections of Botulinum toxin-A &amp; modified Constraint Induced Movement Therapy using a neoprene mitt for 3 hours per day for 2 months. </interventions>
    <comparator>Control Group - Upper limb injections of Botulinum toxin-A &amp; conventional Occupational Therapy for 2 months.</comparator>
    <control>Active</control>
    <interventioncode>Rehabilitation</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bimanual performance (Assisting Hand Assessment)</outcome>
      <timepoint>At baseline, 1 month, 3 months and 6 months post Boutlinum toxin injection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Movement - Quality of Upper Extremity Skills Test (QUEST).</outcome>
      <timepoint>At baseline, 1 month, 3 months and 6 months post Boutlinum toxin injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Spasticity - modified Tardieu scale Muscle tone - modified Ashworth scale Passive Range of Movement - Goniometry.</outcome>
      <timepoint>At baseline, 1 month, 3 months and 6 months post Boutlinum toxin injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Caregiver Assistance</outcome>
      <timepoint>At baseline, 1 month, 3 months and 6 months post Boutlinum toxin injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pediatric Evaluation of Disability Index (PEDI) Frequency of Use - Pediatric Motor Activity Log (PMAL).</outcome>
      <timepoint>At baseline, 1 month, 3 months and 6 months post Boutlinum toxin injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Individual Goal Setting</outcome>
      <timepoint>At baseline, 1 month, 3 months and 6 months post Boutlinum toxin injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Canadian Occupational Performance Measure (COPM) &amp; Goal Attainment Scaling (GAS).</outcome>
      <timepoint>At baseline, 1 month, 3 months and 6 months post Boutlinum toxin injection.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of spastic hemiplegic cerebral palsy; activie movement of the shoulder, elbow, wrist, digits and thumb;  able to grasp a 1 inch cube from a table top and release it into a large container; ability to attend to tasks and follow simple one stage commands; moderate levels of muscle tone and spasticity; no fixed contracture in target group of muscles to be injected with Botulinum toxin-A.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous Botulinum toxin-A injections in the upper limb in the past twelve months; prior upper limb surgery (ie. tendon transfer/tendon lengthening); families do not agree to cease all other alternative upper limb therapies.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Set of random numbers will be used to create a sequence contained in individual opaque envelopes for use by the researcher.  As participants are recruited, the next envelope in the sequence is opened and the participant assigned to the stated group.</concealment>
    <sequence>Subjects are block randomised matched by age (+/- 6 months) using a computer generated set of random number.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>7/07/2003</anticipatedstartdate>
    <actualstartdate>2/09/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>25/09/2008</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>34</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>25/03/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <postcode>3168 - Clayton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Southern Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Allergan Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Southern Health Rehabilitation</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication>1.	Hoare B, Imms C, Villanueva E, Rawicki HB, Matyas T, Carey L. Intensive therapy following upper limb botulinum toxin A injection in young children with unilateral cerebral palsy: a randomized trial. Developmental Medicine &amp; Child Neurology. 2013;55(3):238-47.

2.	Hoare BJ, Imms C, Rawicki HB, Carey L. Modified constraint-induced movement therapy or bimanual occupational therapy following injection of Botulinum toxin-A to improve bimanual performance in young children with hemiplegic cerebral palsy: a randomised controlled trial methods paper. BMC Neurology. 2010;10:58.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health &amp; La Trobe University</ethicname>
      <ethicaddress />
      <ethicapprovaldate>5/01/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>12/01/2003</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Brian Hoare</name>
      <address>Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+61 3 95942270</phone>
      <fax>+61 3 95946444</fax>
      <email>brian.hoare@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Brian Hoare</name>
      <address>Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+61 3 95942270</phone>
      <fax>+61 3 95946444</fax>
      <email>brian.hoare@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Brian Hoare</name>
      <address>Monash Medical Centre, Paediatric Rehabilitation, Level 4
246 Clayton Rd</address>
      <phone>95944620</phone>
      <fax />
      <email>brian.hoare@monashhealth.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>